Loading clinical trials...
Loading clinical trials...
A Phase I/II Trial to Evaluate the Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Complement-Dependent, Antibody-Mediated Rejection Post-Transplant in Highly-HLA Sensitized Patients"
Conditions
Interventions
C1 Esterase Inhibitor
Placebos
Locations
1
United States
Cedars-Sinai medical center
Los Angeles, California, United States
Start Date
August 1, 2011
Primary Completion Date
November 1, 2013
Completion Date
November 1, 2013
Last Updated
March 21, 2017
NCT07415421
NCT06958796
NCT07294547
NCT07224763
NCT06972069
NCT05234463
Lead Sponsor
Stanley Jordan, MD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions